Search

Your search keyword '"Al-Jumayli, Mohammed"' showing total 16 results
Start Over Author "Al-Jumayli, Mohammed" Search Limiters Full Text
16 results on '"Al-Jumayli, Mohammed"'

1. Feasibility trial of STRONG: A digital intervention to improve nutritional management for individuals with esophageal and gastroesophageal junction cancer

Author

Lin, Yu Chen, Pimiento, Jose M., Milano, Jeanine, Riccardi, Diane, Mckinnie, Nakesha, Hume, Emma, Sprow, Olivia, Diaz-Carraway, Sophia, Budnetz, Mara, Hagen, Ryan, Al-Jumayli, Mohammed, Pereira, Allan Lima, Sinnamon, Andrew J., Somasundaram, Ashwin, Permuth, Jennifer B., Tabriz, Amir Alishahi, and Turner, Kea

Published
2025
Full Text
View/download PDF

2. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial

Author

Turner, Kea, Kim, Dae Won, Gonzalez, Brian D., Gore, Laurence R., Gurd, Erin, Milano, Jeanine, Riccardi, Diane, Byrne, Margaret, Al-Jumayli, Mohammed, de Castria, Tiago Biachi, Laber, Damian A., Hoffe, Sarah, Costello, James, Robinson, Edmondo, Chadha, Juskaran S., Rajasekhara, Sahana, Hume, Emma, Hagen, Ryan, Nguyen, Oliver T., Nardella, Nicole, Parker, Nathan, Carson, Tiffany L., Tabriz, Amir Alishahi, and Hodul, Pamela

Published
2024
Full Text
View/download PDF

9. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Author

Saeed, Anwaar, primary, Hildebrand, Hannah, additional, Park, Robin, additional, Al-Jumayli, Mohammed, additional, Abbasi, Saqib, additional, Melancon, Tina, additional, Saeed, Azhar, additional, Al-Rajabi, Raed, additional, Kasi, Anup, additional, Baranda, Joaquina, additional, Williamson, Stephen, additional, and Sun, Weijing, additional

Published
2020
Full Text
View/download PDF

14. Biologic and Immunotherapy Developments in Advanced Hepatocellular Carcinoma

Author

Telfah, Mohammad, Al-Jumayli, Mohammed, Saeed, Anwaar, Telfah, Mohammad, Al-Jumayli, Mohammed, and Saeed, Anwaar

Abstract

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, and the second leading cause of cancer-related mortality worldwide with a very poor 5-year survival. Treatment for HCC includes surgery, liver-directed therapies and systemic therapies. Until 2008, no effective systemic therapy was available for advanced HCC. Sorafenib is the first drug to show improvement in overall survival among patients with advanced HCC in comparison to placebo, and it is approved by U.S. Food and Drug Administration (FDA) as a first-line treatment of advanced HCC. After sorafenib approval, several targeted and immune therapies were tested and showed efficacy in advanced HCC. Lenvatinib has been shown to be non-inferior to sorafenib as first-line treatment. Both nivolumab and regorafenib showed improvement in overall survival among patients with advanced HCC as a second line treatment after progression on sorafenib, and both are FDA approved for this indication. There is a limited role for cytotoxic agents in the treatment of advanced HCC.

Published
2018
Full Text
View/download PDF

16. Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer.

Author

Al-Jumayli M, Choucair K, Al-Obaidi A, Park R, Bansal A, Baranda J, Sun W, and Saeed A

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols pharmacology, Carboplatin pharmacology, Fluorouracil pharmacology, Humans, Paclitaxel pharmacology, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, Chemoradiotherapy methods, Esophageal Neoplasms drug therapy, Fluorouracil therapeutic use, Paclitaxel therapeutic use
Abstract

Background/aim: This study aimed to compare the efficacy and tolerability of pre-operative platinum/5-fluorouracil (P5F) and carboplatin/paclitaxel (CP), in combination with radiation therapy in older adults with locally advanced, stage I-III esophageal cancer., Patients and Methods: We retrospectively reviewed 51 patients aged ≥70 years who underwent chemoradiotherapy followed by esophagectomy for stage I-III esophageal cancer between 2008 and 2018. Pathological complete response (pCR) and survival rates were compared across the two chemotherapy regimen arms., Results: Treatment completion (p=0.28), pCR (p=0.89), and partial response rates were similar across both chemotherapy groups. Overall survival (OS) and disease-free survival (DFS) were similar across both groups with HR=0.80 (p=0.62) and HR=0.72 (p=0.72) respectively., Conclusion: The lesser toxic CP regimen may be used in older patients with locally advanced esophageal cancer, with tumor response and survival rates similar to P5F chemotherapy., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results